Chinook Therapeutics, Inc. (KDNY)
Stock Price:
$15.43 USD
0.00 (0.00%)
Updated Oct 23, 2020 1:27 PM EDT - Market open
Key Info
| Market Cap |
250.48M |
| Revenue (ttm) |
27.96M |
| Net Income (ttm) |
-64.56M |
| Shares Out |
16.23M |
| EPS (ttm) |
-4.00 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 23, 2020 |
| Last Price |
$15.43 |
| Previous Close |
$15.43 |
| Change ($) |
0.00 |
| Change (%) |
0.00% |
| Day's Open |
15.55 |
| Day's Range |
15.00 - 15.60 |
| Day's Volume |
19,067 |
| 52-Week Range |
4.51 - 20.20 |
More Stats
| Market Cap |
250.48M |
| Enterprise Value |
111.48M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
16.23M |
| Float |
8.82M |
| EPS (basic) |
-4.00 |
| EPS (diluted) |
-4.00 |
| FCF / Share |
-4.15 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
3.17M |
| Short Ratio |
0.00 |
| Short % of Float |
35.92% |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
8.96 |
| PB Ratio |
5.37 |
| Revenue |
27.96M |
| Operating Income |
-76.26M |
| Net Income |
-64.56M |
| Free Cash Flow |
-67.09M |
| Net Cash |
139.00M |
| Net Cash / Share |
8.56 |
| Gross Margin |
100.00% |
| Operating Margin |
-272.79% |
| Profit Margin |
-230.90% |
| FCF Margin |
-239.98% |
| ROA |
n/a |
| ROE |
n/a |
| ROIC |
-38.90% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (4)
| Buy |
4 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$27.25*
(76.60% upside)
Low
18.8
Current: $15.43
High
38.0
Target: 27.25
*Average 12-month price target from 3 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|
| Revenue | 17.26 | 15.09 | 17.24 | 50.68 | 72.98 | 13.39 | 0.83 |
| Revenue Growth | 14.39% | -12.48% | -65.99% | -30.55% | 445.07% | 1517.03% | - |
| Gross Profit | 17.26 | 15.09 | 17.24 | 50.68 | 72.98 | 13.39 | 0.83 |
| Operating Income | -90.14 | -101 | -106 | -71.86 | -13.56 | -19.12 | -14.54 |
| Net Income | -82.37 | -95.36 | -91.86 | -91.15 | -39.21 | -17.01 | -16.05 |
| Shares Outstanding | 16.02 | 15.76 | 14.58 | 13.04 | 8.94 | 0.06 | 0.06 |
| Earnings Per Share | -5.15 | -6.05 | -6.30 | -7.00 | -4.40 | -265.30 | -279.00 |
| Operating Cash Flow | -65.51 | -68.76 | -88.86 | -86.08 | 155 | 19.37 | -14.23 |
| Capital Expenditures | -1.26 | -2.32 | -5.15 | -23.89 | -2.17 | -0.78 | -0.17 |
| Free Cash Flow | -66.77 | -71.08 | -94.01 | -110 | 153 | 18.58 | -14.40 |
| Cash & Equivalents | 214 | 267 | 327 | 348 | 416 | 119 | 8.53 |
| Total Debt | 33.44 | - | - | - | - | - | 12.99 |
| Net Cash / Debt | 181 | 267 | 327 | 348 | 416 | 119 | -4.46 |
| Assets | 291 | 358 | 445 | 439 | 482 | 126 | 9.88 |
| Liabilities | 226 | 222 | 208 | 211 | 220 | 47.80 | 16.41 |
| Book Value | 65.60 | 135 | 237 | 227 | 262 | -61.30 | -38.76 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Chinook Therapeutics, Inc. |
| Country |
United States |
| Employees |
43 |
| CEO |
Eric L. Dobmeier |
Stock Information
| Ticker Symbol |
KDNY |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: KDNY |
Description
Chinook Therapeutics, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, an investigational Phase III ready endothelin receptor antagonist for the treatment of IgA nephropathy and other primary glomerular diseases. Its product candidates include BION-1301, an investigational anti-APRIL monoclonal antibody is being evaluated in a Phase Ib trial for IgA nephropathy; and CHK-336, a preclinical development candidate for an undisclosed ultra-orphan kidney disease, as well as research programs for other rare, severe chronic kidney diseases, including polycystic kidney disease. Chinook Therapeutics, Inc. is based in Seattle, Washington.